Original Research J Clin Psychiatry October 2026

From Hospital to Outpatient Care After Long-Acting Injectable Antipsychotic Initiation in Bipolar Disorder: Nationwide Evidence From Taiwan

JCP 2026;87(4):10.4088/JCP.26m16479

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2026;87(4):10.4088/JCP.26m16479 Clinical Summary Patients with bipolar disorder often relapse when daily medication adherence breaks down, leading to emergency visits, hospitalization, and disrupted continuity of care. This study asks a practical question clinicians face every day: after starting a second-generation long-acting injectable antipsychotic, does psychiatric care actually shift away from crisis services and toward planned outpatient follow-up? FAQ What did this study find after starting a second-generation long-acting injectable antipsychotic in bipolar disorder? 11 questions
Key Takeaways Only 500 of 2,919 bipolar disorder initiators met the study’s definition of stable use, underscoring that maintaining label-frequency-concordant long-acting injectable antipsychotic care over 12 months may be a major implementation challenge in routine practice. 6 takeaways Clinical Guide How should clinicians counsel and monitor patients with bipolar disorder after starting a second-generation long-acting injectable antipsychotic based on expected service-use changes? 5 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
Psychiatrist Steven Berkowitz, MD, discusses psychedelic medicine for trauma treatment

Subscribe to read
more articles

Subscribe